Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Active, not recruiting Not applicable Interventional

Surveillance AFter Extremity Tumor surgerY

NCT03944798
View directory record Official record
Conditions
Soft Tissue Sarcoma, Lung Metastases
Interventions
Frequency: Every 3 Months, Frequency: Every 6 Months, Imaging Modality: Chest Radiograph (CXR), Imaging Modality: Chest CT
Other
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
16
States / cities
Sacramento, California • Hartford, Connecticut • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 21, 2026, 10:53 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 21, 2026, 10:53 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Episodic Future Thinking and Future Thinking Priming for Smoking Cessation

NCT04297332
View directory record Official record
Conditions
Tobacco-Related Carcinoma
Interventions
Behavioral Intervention, Informational Intervention, Nicotine Replacement, Telephone-Based Intervention
Behavioral · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

NCT00000893
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 16 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 21, 2026, 10:53 PM EDT
Active, not recruiting Phase 2 Interventional

Semaglutide Therapy for Alcohol Reduction (STAR)

NCT06015893
View directory record Official record
Conditions
Addiction, Alcohol Use Disorder
Interventions
Take Control, Semaglutide
Behavioral · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 110 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of GLA on Human Volunteers

NCT01397604
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GLA-AF, GLA-SE, Squalene
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

NCT02195232
View directory record Official record
Conditions
Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
Interventions
Isoquercetin
Drug
Lead sponsor
Jeffrey Zwicker, MD
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • West Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 21, 2026, 10:53 PM EDT
Active, not recruiting Phase 2 Interventional

FDOPA PET and Nutritional Support in Parkinson's Disease

NCT04459052
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
N acetyl cysteine, [F-18] Fluorodopa Positron Emission Tomography
Dietary Supplement · Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
30 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Not applicable Interventional

EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures

NCT01681225
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Esophageal-pressure guided mechanical ventilation, High PEEP mechanical ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
La Jolla, California • Stanford, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

NCT00522925
View directory record Official record
Conditions
Hypertension
Interventions
PS433540, placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Tempe, Arizona • Lincoln, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 21, 2026, 10:53 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial

NCT07104240
View directory record Official record
Conditions
Human Papillomavirus-Related Carcinoma
Interventions
Best Practice, Educational Intervention, Health Promotion and Education, Internet-Based Intervention
Other
Lead sponsor
Emory University
Other
Eligibility
9 Years and older
Enrollment
1,836 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 10:53 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

NCT04589650
View directory record Official record
Conditions
PIK3CA-related Overgrowth Spectrum (PROS)
Interventions
Alpelisib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Days to 100 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 10:53 PM EDT
Terminated Phase 3 Interventional

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00324324
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
moxifloxacin hydrochloride, Placebo
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 21, 2026, 10:53 PM EDT
Not listed Phase 1Phase 2 Interventional

APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee

NCT02210468
View directory record Official record
Conditions
Pain, Osteoarthritis
Interventions
APIC-CF, 4 cc, APIC-CF, 2 cc, Placebo Comparator: Saline
Device · Other
Lead sponsor
Cytonics Corporation
Industry
Eligibility
21 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Townsend, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Surgical Theater's Surgery Rehearsal Platform

NCT02099318
View directory record Official record
Conditions
Cerebral Aneurysm Unruptured, Cerebral Aneurysm Ruptured
Interventions
Active SRP cases, Control cases
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

NCT02633020
View directory record Official record
Conditions
Type II Refractory Celiac Disease (RCD-II), In-situ Small Bowel T-cell Lymphoma
Interventions
AMG 714, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Not applicable Interventional

Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study

NCT01252524
View directory record Official record
Conditions
Diabetes Mellitus Type II
Interventions
Placebo, Calcium polycarbophil
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

NCT02436824
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
AB001 patch, Placebo patch
Drug · Other
Lead sponsor
Frontier Biotechnologies Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Miami, Florida • Naples, Florida • Marietta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 21, 2026, 10:53 PM EDT
Withdrawn Phase 3 Interventional

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2008 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

NCT02633397
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Riociguat, Placebo
Drug
Lead sponsor
Mark Gladwin
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
20
States / cities
Oakland, California • Washington D.C., District of Columbia • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 21, 2026, 10:53 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

NCT06059391
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hematopoietic Cell Transplantation Conditioning Regimen, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Pheresis, Placebo Administration, Stem Cell Mobilization Therapy
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

NCT00890825
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
AZD6244, docetaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Not applicable Interventional

A Study to Assess the Role of a Gluten Free-dairy Free (GFCF) Diet in the Dietary Management of Autism Associated Gastrointestinal Disorders

NCT01116388
View directory record Official record
Conditions
Autism, Gastrointestinal Symptoms
Interventions
GFCF product with GFCF diet, product containing gluten and casein (milk protein) with GFCF diet
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 21, 2026, 10:53 PM EDT